|
Synonyms: GNC 038 | GNC-038 | GNC038
Compound class:
Antibody
Comment: Emfizatamab (GNC-038) is a humanized immunotherapeutic monoclonal antibody that is engineered to engage 4 molecular targets (tetra-specific), to provide immunostimulatory and antineoplastic activities as an approach to treat B cell malignancies. The protein targets are CD19, CD3e, PD-L1 and 4-1BB. Emfizatamab is designed to crosslink CD19-expressing tumour B cells with cytotoxic T lymphocytes (via CD3e binding). It also targets PD-L1 on the tumour cells (preventing interaction with the inhibitory T cell checkpoint protein PD-1), and engagement of 4-1BB (TNFRSF9) acts as a co-stimulatory signal on T cells that is proposed to enhance anti-tumour activity. Likely one of the so-called 'guidance and navigation control (GNC)' proteins that are claimed in Sichuan Baili Pharmaceutical/Systimmune patent US20210024630A1 [1].
|
| No information available. |
Summary of Clinical Use  |
| Clinical studies are underway to investigate emfizatamab's efficacy against B cell cancers. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | Phase 1/Phase 2 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT04606433 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Non-Hodgkin Lymphoma | Phase 1 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1/Phase 2 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT05189782 | Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma | Observational | Ruijin Hospital | ||
